MedTrace Logo

Model for Heart Failure ExAcerbation Reduction Trial

NCT01726985 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 230

Last updated 2017-04-11

No results posted yet for this study

Summary

Heart failure is the leading cause of hospitalizations and readmissions in the United States and is a tremendous economic strain on our healthcare system. There is currently, based on national averages, a 30% readmission rate and 10% mortality rate within 3 months of being hospitalized for heart failure. Retrospective studies have shown benefit to using biomarkers such as BNP to guide inpatient heart failure management. Our own CCF retrospective study showed that decreasing NT-ProBNP by 23%, making patients fluid negative by more than 1.3L, and discharging patients with serum sodium above 135 reduces readmission rates significantly. The purpose of this study is to prospectively use the above mentioned goals in the treatment of heart failure in order to reduce heart failure readmission and mortality rates.

Conditions

  • Acute on Chronic Heart Failure

Interventions

OTHER

Parameter Based Clinical Disposition

Parameter Based Clinical Disposition' Physicians will initiate / titrate medications and obtain consults as usual but are highly encourage to keep patients in the hospital until at least 2 of the following 3 criteria are met: * NT-ProBNP reduction of \> 23% from peak value during admission * Fluid Reduction of \> 1.3L (orders for I/O q8h required) * Serum Sodium of \> 135 mmol/L the day of planned discharge

Sponsors & Collaborators

  • Cleveland Clinic Florida

    lead OTHER

Principal Investigators

  • Marlow Hernandez · Cleveland Clinic Florida

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01726985 on ClinicalTrials.gov